Home › FDA Approves Pediatric Indication for EMEND (aprepitant) Capsules in Combination with Other Antiemetic Agents
 

Keywords :   


FDA Approves Pediatric Indication for EMEND (aprepitant) Capsules in Combination with Other Antiemetic Agents

2015-09-02 14:00:00| Merck.com - Corporate News

Dateline City: KENILWORTH, N.J. KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) for EMEND (aprepitant) capsules, a substance P/neurokinin 1 (NK1) receptor antagonist. Language: English Contact: MerckMedia:Doris Li, 908-740-1903An Phan, 908-255-6325orInvestors:Justin Holko, 908-740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more

Tags: combination agents indication pediatric

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
17.05Henkel Laundry Patent Details Transfer of Encapsulated Fragrance with Dryer Balls
17.05PNWSCT Coatings Fest 2024 Issues Call for Papers
17.05USDA awards $22.2 million to protect livestock health
17.05USDA awards $22.2 million to protect livestock health
17.05Smithfield Foods donates $12K to expand Dolly Parton's Imagination Library
17.05More people seek help for debts as fee scrapped
17.05Hunt hints at another National Insurance tax cut
17.05Alan Bates rejects second Post Office compensation offer
More »